![](https://washingtonexec.com/wp-content/uploads/2017/03/mike_deutsch.jpg)
Digital services provider CollabraLink Technologies, Inc. is one of the awardees of a $140 million blanket purchase agreement by the Food and Drug Administration’s Center for Drug Evaluation & Research.
This new 5-year, multiple-award vehicle will serve as a catalyst for a digital modernization effort aimed at automating key regulatory review processes across multiple CDER Offices.
“As has been demonstrated over the past year, there is arguably no more important mission on our national agenda than safeguarding health via safe and effective drugs,” said CollabraLink CGO Mike Deutsch.
FDA’s modern acquisition approach to this procurement process was conducted in multiple stages and tested partners like CollabraLink to demonstrate their agile and user experience processes, and technical acumen via a prototype design challenge. The results were then presented to FDA CDER stakeholders.
“Improving business process management is a key pillar in CDER’s enterprise strategy, and this contract will help to facilitate improved health outcomes and quality of life for all Americans,” Deutsch said. CollabraLink is honored to play a role in supporting FDA-CDER in the fulfillment of its vital mission objectives.”